Diabetic Kidney Disease: Act Now or Pay Later—World Kidney Day, 11 March 2010
2010; Wiley; Volume: 14; Issue: 1 Linguagem: Inglês
10.1111/j.1744-9987.2009.00804.x
ISSN1744-9987
AutoresRobert C. Atkins, Paul Zimmet,
Tópico(s)Renal Diseases and Glomerulopathies
ResumoTherapeutic Apheresis and DialysisVolume 14, Issue 1 p. 1-4 Diabetic Kidney Disease: Act Now or Pay Later—World Kidney Day, 11 March 2010 We Must Act on Diabetic Kidney Disease Robert C Atkins, Robert C Atkins Department of Epidemiology and Preventative Medicine, Monash University, andSearch for more papers by this authorPaul Zimmet, Paul Zimmet Baker IDI Heart and Diabetes Institute, Melbourne, AustraliaEmail: [email protected]Search for more papers by this author Robert C Atkins, Robert C Atkins Department of Epidemiology and Preventative Medicine, Monash University, andSearch for more papers by this authorPaul Zimmet, Paul Zimmet Baker IDI Heart and Diabetes Institute, Melbourne, AustraliaEmail: [email protected]Search for more papers by this author First published: 12 February 2010 https://doi.org/10.1111/j.1744-9987.2009.00804.xCitations: 4 Reprinted with permission from the International Society of Nephrology. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 International Diabetes Federation and International Society of Nephrology. Diabetes and Kidney Disease: Time to Act. Brussels: International Diabetes Federation and International Society of Nephrology, 2003. 2 Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–7. 3 King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–31. 4 Yoon K, Lee JH, Kim JW et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681–8. 5 Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: D Gan, ed. Diabetes Atlas, 3rd edn. Brussels: International Diabetes Federation, 2006; 15–109. 6 Reutens AT, Prentice L, Atkins R. The epidemiology of diabetic kidney disease. In: J Ekoé et al., ed. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: John Wiley & Sons, 2008; 499–518. 7 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007; 239–54. 8 S McDonald, L Excell, B Livingston, eds. ANZDATA Registry Report 2008, Appendix II. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 2008; 1–97. 9 Yamagata K, Iseki K, Nitta K et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008; 12: 1–8. 10 Lysaght M. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 2002; 13: S37–40. 11 Adler A, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–32. 12 Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832–9. 13 Parving H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057–63. 14 Ninomiya T, Perkovic V, De Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813–21. 15 Dunstan D, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829–34. 16 White S, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban SJ. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 2008; 188: 204–8. 17 Whaley-Connell A, Sowers JR, McCullough PA et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53(4 Suppl 4): S11–21. 18 Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008; 4: 2–3. 19 Holman R, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89. 20 Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008; 25(Suppl 2): 25–9. 21 Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91. 22 Patel A; ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40. 23 ADVANCE Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72. 24 Zoungas S, De Galan BE, Ninomiya T et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 2009; 32: 2068–74. 25 Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51. 26 Parving H, Lehnert H, Brøchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8. 27 Lewis E, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851–60. 28 Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009; 18: 107–11. Citing Literature Volume14, Issue1February 2010Pages 1-4 ReferencesRelatedInformation
Referência(s)